modelR01AA14
Extends from Pharmacokinetic.Models.PK_1C.
Information
| name: | Epinephrine | |
| ATC code: | R01AA14 | route: | intranasal |
| compartments: | 1 | |
| dosage: | 2 | mg |
| volume of distribution: | 0.3 | L |
| clearance: | 1300 | mL/min |
| other parameters in model implementation | ||
Epinephrine (also known as adrenaline) is a naturally occurring catecholamine hormone and neurotransmitter used primarily in emergency medicine. It is indicated for the treatment of severe allergic reactions (anaphylaxis), cardiac arrest, and as a vasoconstrictor in shock. It is approved and widely used today in various clinical settings.
Pharmacokinetics
Pharmacokinetic parameters estimated for adult healthy individuals. No direct publication was found for intranasal/ATC R01AA14-specific administration; values are extrapolated from general human PK and alternative routes (intramuscular/intravenous) as reference.
References
Yoo, H, et al., & Jusko, WJ (2015). Mechanism-based population pharmacokinetic and pharmacodynamic modeling of intravenous and intranasal dexmedetomidine in healthy subjects. European journal of clinical pharmacology 71(10) 1197–1207. DOI:10.1007/s00228-015-1913-0 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26233335
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)